Download PDF
Thromb Haemost 1970; 23(03): 417-422
DOI: 10.1055/s-0038-1654067
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Activation of Hageman Factor by α-Adrenergic Stimulation

D. G McKay M. D.,
1   Department of Pathology University of California School of Medicine San Francisco General Hospital 1001 Potrero Avenue San Francisco, California 94110
,
J.-G Latour Ph. D.
1   Department of Pathology University of California School of Medicine San Francisco General Hospital 1001 Potrero Avenue San Francisco, California 94110
,
Mary H. Parrish B. S.
1   Department of Pathology University of California School of Medicine San Francisco General Hospital 1001 Potrero Avenue San Francisco, California 94110
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

The infusion of epinephrine in high doses produces disseminated intravascular coagulation by activation of Hageman factor. The effect is blocked by phenoxybenz-amine and is therefore due to stimulation of α-adrenergic receptor sites.

 

  • References

  • 1 Bell W. N, Alton H. G. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature (Lond.) 174: 880 1954;
    CrossrefPubMedGoogle Scholar
  • 2 Fantl P, Morris K. N, Sawyer B. J. Repair of cardiac defect in patient with Ehlers-Danlos syndrome and deficiency of Hageman factor. Brit. Med. J I: 1202 1961;
    PubMedGoogle Scholar
  • 3 Josso F, Prou-Wartelle O, Charles J. Durée de vie du facteur Hageman (facteur XII). Nouv. Rev. franç. Hémat 4: 454 1964;
    PubMedGoogle Scholar
  • 4 Kellermeyer B. W, Breckenridge B. T. The inflammatory process in acute gouty arthritis. I. Activation of Hageman factor by sodium urate crystals. J. Lab. clin. Med 65: 307 1965;
    PubMedGoogle Scholar
  • 5 Margolis J. The kaolin clotting time; a rapid one-stage method for diagnosis of coagulation defects. J. clin. Path. (Lond.) 11: 406 1958;
    CrossrefPubMedGoogle Scholar
  • 6 Melmon K. L, Cline M. J. The interaction of leukocytes and the kinin system. Biochem. Pharmacol Suppl.: 271 1968;
    PubMedGoogle Scholar
  • 7 Müller-Berghaus G, Davidson E, McKay D. G. Prevention of the generalized Shwartzman reaction in pregnant rats by alpha-adrenergic blockade. Effects on the coagulation mechanism. Obstet, and Gynec 30: 774 1967;
    PubMedGoogle Scholar
  • 8 Müller-Berghaus G, McKay D. G. Prevention of the generalized Shwartzman reaction in pregnant rats by α-adrenergic blocking agents. Lab. Invest 17: 276 1967;
    PubMedGoogle Scholar
  • 9 Niewiarowski S, Bankowski E, Fiedoruk T. Adsorption of Hageman factor (factor XII) on collagen. Experientia (Basel) 20: 367 1964;
    CrossrefPubMedGoogle Scholar
  • 10 Nossel H. L. The contact phase of blood coagulation. 138-139. F. A. Davis; Philadelphia: 1964
    Google Scholar
  • 11 Nossel H. L, Niemetz J. A normal inhibitor of the blood coagulation contact reaction product. Blood 25: 712 1965;
    PubMedGoogle Scholar
  • 12 Proctor R. R, Rapaport S. I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Amer. J. clin. Path 36: 212 1961;
    PubMedGoogle Scholar
  • 13 Ratnoff O. D. Progress in hematology. Brown E. B, and Moore C. V. Eds. Vol.5. 204-245. Grune & Stratton; New York: 1966
    Google Scholar
  • 14 Ratnoff O. D. Activation of Hageman factor by L-homocystine. Science 162: 1007 1968;
    PubMedGoogle Scholar
  • 15 Whitaker A. N, McKay D. G, Gsavossy I. Studies of catecholamine shock. I. Disseminated Intravascular coagulation. Amer. J. Path 56: 153 1969;
    PubMedGoogle Scholar